QLT

QLT shifted from drug development to a royalty and licensing model after selling its commercial operations. It now generates revenue from milestone payments and royalty streams from therapies it previously developed or in-licensed (public record). The firm does not actively invest in new R&D.

Yes, QLT maintains an office in Vancouver, British Columbia, alongside a New York headquarters (per the firm's official records). The firm also had a European presence historically, but that appears wound down.

Investment decisions are made by QLT's executive team, which has not been publicly named in recent years. The firm's public filings indicate a small leadership group focused on royalty asset management and financial oversight.

No — QLT is a publicly held asset manager that operates as a royalty corporation. It does not have the structure or mandate of a family office, despite once being categorized by some data vendors as such. It lacks family-based wealth origin or multi-generational capital management.

QLT's primary known royalty stream was from Visudyne (verteporfin) for wet AMD, licensed to Novartis (public record). Other legacy assets include dermatology treatments and photodynamic therapy compounds, though specific current holdings are not publicly updated.

No — QLT no longer makes active investments or product development. Its post-sale model focuses on managing existing royalty and licensing agreements without deploying capital into new ventures or partnerships.